GILD stock news
This page provides real-time market news, earnings updates, and company announcements related to Gilead Sciences, Inc. (GILD).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-17 13:01 EST
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note
Finviz2026-03-03 23:54:38
Ligand to Participate in March Investor Conferences
Finviz2026-03-04 12:03:13
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Finviz2026-03-05 12:03:11
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Finviz2026-03-09 12:03:10
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Finviz2026-03-09 20:06:46
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Finviz2026-03-09 22:51:54
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
Finviz2026-03-10 07:36:48
Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's,Qualcomm, Rivian, Strategy and More
Finviz2026-03-10 12:09:09
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
Finviz2026-03-10 14:39:58
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Finviz2026-03-17 12:09:49
Gilead Sciences (GILD.US) initiates Phase III clinical trial for CD19/CD20 CAR-T cell therapy
老虎证券2026-03-19 14:10:00
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-23 11:33:55
According to sources familiar with the matter, merger talks between biopharmaceutical giant Gilead Sciences and biotechnology company Ouro Medicines have entered a key stage.
老虎证券2026-03-23 16:59:31
Gilead Sciences will pay approximately $1.5 billion in cash as an upfront payment to investors of the privately held company Ouro.
老虎证券2026-03-23 17:00:32
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Finviz2026-03-23 20:09:47
Gilead acquires biotechnology company Ouro for up to $2.2 billion
格隆汇2026-03-24 02:03:13
Gilead plans to acquire Ouro Medicines for up to $2.175 billion
格隆汇2026-03-24 03:20:40
Nurix Therapeutics to Participate in Upcoming Investor Conference
Finviz2026-04-07 11:03:42
RBC Capital raises Gilead Sciences' price target to $123
格隆汇2026-04-08 09:37:29
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Finviz2026-04-08 10:03:59
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Finviz2026-04-09 11:03:39
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Finviz2026-04-09 12:06:07
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Finviz2026-04-14 20:06:55
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Finviz2026-03-09 20:06:46
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Finviz2026-03-09 22:51:54
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
Finviz2026-03-10 07:36:48
Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's,Qualcomm, Rivian, Strategy and More
Finviz2026-03-10 12:09:09
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
Finviz2026-03-10 14:39:58
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Finviz2026-03-17 12:09:49
Gilead Sciences (GILD.US) initiates Phase III clinical trial for CD19/CD20 CAR-T cell therapy
老虎证券2026-03-19 14:10:00
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-23 11:33:55
According to sources familiar with the matter, merger talks between biopharmaceutical giant Gilead Sciences and biotechnology company Ouro Medicines have entered a key stage.
老虎证券2026-03-23 16:59:31
Gilead Sciences will pay approximately $1.5 billion in cash as an upfront payment to investors of the privately held company Ouro.
老虎证券2026-03-23 17:00:32
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Finviz2026-03-23 20:09:47
Gilead acquires biotechnology company Ouro for up to $2.2 billion
格隆汇2026-03-24 02:03:13
Gilead plans to acquire Ouro Medicines for up to $2.175 billion
格隆汇2026-03-24 03:20:40
Nurix Therapeutics to Participate in Upcoming Investor Conference
Finviz2026-04-07 11:03:42
RBC Capital raises Gilead Sciences' price target to $123
格隆汇2026-04-08 09:37:29
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Finviz2026-04-08 10:03:59
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Finviz2026-04-09 11:03:39
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Finviz2026-04-09 12:06:07
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Finviz2026-04-14 20:06:55
GILD stock chart
GILD stock detailsGILD stock price change
On the last trading day, GILD stock closed at 138.55 USD, with a price change of -0.87% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more